DSGN vs. EDIT, VYGR, ATAI, SGMO, DTIL, AUTL, ALGS, CGEM, PHAT, and CRGX
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Editas Medicine (EDIT), Voyager Therapeutics (VYGR), Atai Life Sciences (ATAI), Sangamo Therapeutics (SGMO), Precision BioSciences (DTIL), Autolus Therapeutics (AUTL), Aligos Therapeutics (ALGS), Cullinan Therapeutics (CGEM), Phathom Pharmaceuticals (PHAT), and CARGO Therapeutics (CRGX). These companies are all part of the "medical" sector.
Design Therapeutics (NASDAQ:DSGN) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by insiders. Comparatively, 1.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Design Therapeutics has higher earnings, but lower revenue than Editas Medicine. Design Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Design Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 24.11%. Editas Medicine has a consensus target price of $11.50, indicating a potential upside of 205.04%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Design Therapeutics.
Design Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -288.59%. Design Therapeutics' return on equity of -18.48% beat Editas Medicine's return on equity.
Design Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
Editas Medicine received 294 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 53.71% of users gave Editas Medicine an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.
In the previous week, Editas Medicine had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.30 beat Editas Medicine's score of -0.36 indicating that Design Therapeutics is being referred to more favorably in the media.
Summary
Editas Medicine beats Design Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
